The exclusive secretion of ASAH1 by CD133+ GSCs can be utilized as an advantage by developing an antibody or tumor vaccine against the secreted ASAH1, allowing a therapy specifically targeting glioblastoma. The gene discussed is PROM1; the disease is neoplasm.